Aviptadil for COVID-19: A Case Study and Call to Action About the Challenges of Research During a Global Pandemic
- PMID: 36227034
- PMCID: PMC9555556
- DOI: 10.1097/CCM.0000000000005686
Aviptadil for COVID-19: A Case Study and Call to Action About the Challenges of Research During a Global Pandemic
Conflict of interest statement
Dr. Auld has disclosed that she does not have any potential conflicts of interest.
Comment on
-
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.Crit Care Med. 2022 Nov 1;50(11):1545-1554. doi: 10.1097/CCM.0000000000005660. Epub 2022 Aug 29. Crit Care Med. 2022. PMID: 36044317 Free PMC article. Clinical Trial.
References
-
- Kaiser Health News: Study: Death 40% More Likely From Omicron Than From Flu. 2022. Available at: https://khn.org/morning-breakout/study-death-40-more-likely-from-omicron.... Accessed September 5, 2022
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
